anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

There are no available data on Veregen use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, sinecatechins did not cause malformations, but did affect the developing fetus in the presence of maternal toxicity when given to pregnant rabbits and rats by intravaginal or systemic routes of administration during the period of organogenesis (see Data). The available data do not allow the calculation of relevant comparisons between the systemic exposure of sinecatechins observed in the animal studies to the systemic exposure that would be expected in humans after topical use of Veregen.

Data

Embryo-fetal development studies were conducted in rats and rabbits using intravaginal and systemic routes of administration, respectively. Oral administration of sinecatechins during the period of organogenesis (gestational Days 6 to 15 in rats or 6 to 18 in rabbits) did not cause treatment-related malformations or effects on embryo-fetal development at doses of up to 1,000 mg/kg/day.

In the presence of maternal toxicity (characterized by marked local irritation at the administration sites and decreased body weight and food consumption) in pregnant female rabbits, subcutaneous doses of 12 and 36 mg/kg/day of sinecatechins during the period of organogenesis (gestational Days 6 to 19) resulted in corresponding influences on fetal development including reduced fetal body weights and delays in skeletal ossification. No treatment-related effects on embryo-fetal development were noted at 4 mg/kg/day. No malformations were noted at any of the doses evaluated in this study.

A combined fertility and embryo-fetal development study using daily vaginal administration of Veregen to rats from Day 4 before mating and throughout mating until Day 17 of gestation did not show treatment-related effects on fertility, malformations, or embryo-fetal development at doses up to 0.15 mL/rat/day. This dose corresponds to approximately 150 mg/rat/day.

A pre- and post-natal development study was conducted in rats using vaginal administration of Veregen at doses of 0.05, 0.10 and 0.15 mL/rat/day from Day 6 of gestation through parturition and lactation. The high and intermediate dose levels of 0.15 and 0.10 mL/rat/day resulted in an increased mortality of the F0 dams, associated with indications of parturition complications. The high dose level of 0.15 mL/rat/day also resulted in an increased incidence of stillbirths. There were no other treatment-related effects on pre- and post-natal development, growth, reproduction and fertility at any dose tested.
Porcine Post Weaning Diarrhoea (PWD) is one of the most important swine disease worldwide, caused by Enterotoxigenic Escherichia coli (ETEC) strains able to provoke management, welfare and sanitary issues. ETEC is determined by proteinaceous surface appendages. Numerous studies conducted by now in pigs have demonstrated, at the enterocytes level, that, the genes mucin 4 (MUC4) and fucosyltransferase (FUT1), coding for ETEC F4 and F18 receptors respectively, can be carriers of single nucleotide polymorphisms (SNPs) associated with natural resistance/susceptibility to PWD. The latter aspect was investigated in this study, evaluating the SNPs of the MUC4 and FUT1 genes in slaughtered pigs reared for the most in Central Italy. Genomic DNA was extracted from 362 swine diaphragmatic samples and then was subjected to the detection of known polymorphisms on MUC4 and FUT1candidate target genes by PCR-RFLP. Some of the identified SNPs were confirmed by sequencing analysis. Animals carrying the SNPs associated with resistance were 11% and 86% for the FUT1 and MUC4 genes respectively. Therefore, it can be assumed that the investigated animals may be an important resource and reservoir of favorable genetic traits for the breeding of pigs resistant to enterotoxigenic E.coli F4 variant.
FIELD: chemistry of peptides, immunology. SUBSTANCE: invention relates to polypeptides used as immunological reagents for assay, prophylaxis and treatment of infections induced by hepatitis C virus. Invention describes a new polypeptide including truncated sequence of hepatitis C virus and containing epitope of hepatitis C virus of the formula aa x -aa y . This polypeptide is able to induce immune response in humans and a means amino acid; x and y are whole numbers at condition that y - x ≥ 14; aa x -aa y  means part of amino acid sequence in figure 1 and x is taken among the group: 66, 413, 465, 540, 1218, 1940, 2244, 2281. Indicated polypeptide can contain an optional sequence of N-terminal amino acids corresponding to the sequence of polypeptide of hepatitis C virus which adjoins to N-end of amino acid aa x  to which it bound or an optional sequence of C-terminal amino acids corresponding to the sequence of polypeptide of hepatitis C virus which adjoins to C-end of amino acid aa y  to which it bound. The total amount of additional amino acids does not exceed 15 for aa 413 -aa 427 , 4 for aa 465 -aa 480 , 85 for aa 540 -aa 554 , 10 for aa 2244 -a 2258  and 30 for aa 2281 -aa 2300 . Invention describes method of assay of antibody presence and method of induction of immune response also. EFFECT: improved method of synthesis, new polypeptide indicated above. 6 cl, 2 tbl
A prospective, observational study, determined as non-significant risk by the Central IRB, to assess and improve performance of a non-invasive ICP estimation system. The development of non-invasive systems is intended to replace the need for invasive ICP monitors. Participants serve as their own controls with concurrent, synchronous measurements of ICP (measured invasively as per standard clinical practice), Arterial Blood Pressure (ABP- measured invasively as per standard clinical practice), and measurements of a novel non- invasive cerebral blood-flow index (CBFi) from the CoMind One EFS device. These signals will be recorded simultaneously. The ABP and CBFi will serve as inputs to a model which outputs a non-invasive estimate of ICP, and the invasive ICP signal will be used to supervise and evaluate the performance of the non-invasive ICP estimation model. A large volume of data shall be collected for the purposes of training and testing the non-invasive ICP model. The Sponsor will report limits of agreement (LOA) between data-driven estimates of ICP and the invasively measured signal. In addition, this study will compare metrics built on non-invasive estimation of ICP or CBFi that indicate the state of CAR, and the limits of Autoregulation.
To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
<P>PROBLEM TO BE SOLVED: To provide a skin care preparation for external use, obtained by formulating black vinegar or an extract of the black vinegar.  <P>SOLUTION: The black vinegar is obtained by fermenting/maturing cereals such as a rice and a wheat for two or more months regardless of the cleaning degree. A longer maturing time is preferable because the longer the maturing period becomes, the more the contents of components such as vitamins, minerals and amino acids are increased. The black vinegar has antiaging activities, bleaching activities, antiinflammatory activities, high humectant activities and antioxidant activities, and the application thereof to the skin care preparation for external use is effective. As a result, the black vinegar is utilizable for a drug, a quasi drug and a cosmetic.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Motivation represents a core aspect of goal-directed behavior as it determines how much effort individuals are willing to invest to reach their goals. While research on effort-based decision-making focuses mainly on effort preferences in younger adults, loss of motivation might be a key component of the apathetic tendencies frequently seen in older adults. However, an open question refers to which brain mechanisms underlie motivational processes in older adults. The investigators have recently shown that the frontopolar cortex plays a crucial in motivating the exertion of rewarded effort in younger adults (Soutschek et al., 2018, Biological Psychiatry). The goal of the current study is to determine whether frontopolar cortex plays a crucial role for motivation also in older adults and may thus be a promising target for improving the motivation deficits in healthy aging. 30 older participants (65-80 years) perform computer-based experimental tasks measuring the propensity to exert cognitive or physical effort for monetary rewards. During task performance, participants receive 1 mA anodal or sham transcranial direct current stimulation (tDCS) over their frontopolar cortex. The study tests whether tDCS over frontopolar cortex allows modulating participants' motivation to engage in rewarded effort.
294,299. Arkell, B. May 2, 1927. Chewing-preparations; coatings for medicines. -Magnesium oxide or hydroxide or an equivalent magnesium compound is incorporated in chewing-gum so as to act as an acid-neutralizing agent in the mouth. The magnesia may be mixed with the gum mass or may be in part mixed with the sugar coating. The gum may be composed of chicle, purified rubber, asphalts, paraffin, or mixtures thereof, and, in addition to the magnesia, sugar, and flavourings may be added. According to an example, a gum composition consists of paloge, chicle, sugar, glucose, magnesium hydroxide, and peppermint flavouring. This mass is formed into pellets which are coated with sugar containing magnesium oxide or hydroxide and a flavouring substance.
The invention aims to provide a Chinese medicinal composition for auxiliary treatment of sepsis. The Chinese medicinal composition is prepared after repeated verification by clinical tests, and is accord with the theories of traditional Chinese medicine. Agrimony, peony flowers, Solidago decurrens, plantain lily, saffron crocus, and senecio are adopted as monarch drugs to clear away heat and toxic materials and diminish inflammation. Ginseng flowers, lotus seeds, lily, albizia flowers, herb of white clover, and medlar are taken as minister drugs to enhance immunity, tonify deficiency and treat collapse, reinforcing qi and nourishing yin, strengthen the body resistance to consolidate the constitution. Radices lithospermi, Adder tongue herb, Semen Pharbitidis, seeds of Chinese Honeylocust, lucid ganoderma, and Salvia Miltiorrhiza are taken as adjuvant drugs to clear hollow viscera and purge excess fire. Effects of all the drugs are coordinated. Limonium bicolor, Radix Zanthoxyli, Euonymus alatus, cassia twigs, Protentilla Freyniana Bornm and roots of chinese barberry are adopted as guide drugs to promote blood circulation and remove blood stasis, clear and activate channels and collaterals, and guide all the drugs to disease affected parts directly.
Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention provides a lopinavir and ritonavir compound high-uniformity nano co-dispersion body. The lopinavir and ritonavir compound high-uniformity nano co-dispersion body consists of lopinavir and ritonavir which are taken as active ingredients, a dispersing aid, an anti-agglormeration material, a dispersing stabilizer, a dispersion supporter and a lubricant. The lopinavir and ritonavir which are taken as active ingredients account for 25%-60%. The lopinavir and ritonavir compound high-uniformity nano co-dispersion body prepared by the preparation method disclosed by the invention can be prepared into a single-dose preparation according to a normal method. According to a dissolution rate experiment, the preparation disclosed by the invention has release amount of 40%-80% within 30 minutes. The preparation prepared by the dispersion body disclosed by the invention is high in dissolution rate, and can be used for improving the bioavailability. The lopinavir and ritonavir compound high-uniformity nano co-dispersion body prepared by the preparation method disclosed by the invention satisfies and is superior to mixing uniformity standards. The preparation method disclosed by the invention is simple and easy to implement, can be used for popularizing application of a nano mechanical grinding technology on the pharmaceutical industry and promoting the development of the technology, and is suitable for industrial production and greater in application value.
PROBLEM TO BE SOLVED: To obtain the subject composition hardly damaging a tooth because of a low grinding force, and having a high cleaning powder by including potassium sulfate in a granular shape. SOLUTION: This toothpaste composition contains potassium sulfate in a granular shape and further preferably an inorganic grinding component. The particle diameter of the potassium sulfate is preferably 1-1,000 μm, especially 20-50 ×m. The compounded amount is ordinarily 0.1-60 wt.%, preferably 10-30 wt.% of the whole composition. Calcium hydrogen phosphate anhydrate, calcium hydrogen phosphate dihydrate or the like is cited as the inorganic grinding agent and the compounded amount thereof is preferably 10-50 wt.%, especially 20-30 wt.% of the whole composition.  Preferably, the method for preparing the composition comprises, for example, compounding the potassium sulfate in a saturating amount with the mixture of the components without the granular potassium sulfate, mixing and dissolving the compounded product, and further compounding the granular potassium sulfate having a prescribed particle diameter and particle diameter distribution therewith.
In fear of harmful effect of hypoxia, oxygen therapy is commonly used, especially in critically ill patients in intensive care units (ICUs). However, hyperoxia can be harmful too. Examples are myocardial infarction (MI) patients and patients resuscitated to return of spontaneous circulation after cardiac arrest. In Air Versus Oxygen in Myocardial Infarction (AVOID) trial, Meyhoff and colleagues proved hyperoxia caused more cardiac injury in patients with ST-elevation MI but without hypoxia. Kilgannon and colleagues found that arterial hyperoxia following resuscitation from cardiac arrest were associated with increased in-hospital mortality, and a pulse oxygen saturation (SpO2) of 94-98% was recommended.

Recently, Panwar and colleagues found that compared to liberal oxygen strategy (SpO2 ≥96%), conservative oxygen strategy (SpO2 of 88%-92%) was feasible in patients receiving invasive mechanical ventilation. Girardis and colleagues found control oxygen therapy (targeting SpO2 of 94%-98% or PaO2 of 70-100mmHg) resulted lower ICU mortality than conventional oxygen therapy (SpO2 ≥97%) in the randomized clinical trial called Oxygen-ICU. However, the Oxygen-ICU trial was single-centered, early-terminated with only 480 patients included and led to an unplanned interim analysis. In this larger multicenter trial, investigators hypothesized that a relative low SpO2 directed oxygen therapy was safe and would reduced the 28-day mortality in patients staying longer than 72 hours in ICUs.
In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
Half of all subjects will receive sham HD-tDCS (randomly assigned). A ramp-up of 1 minute will be used to induce the same feelings as during the active tDCS, but will then stop the stimulation. A short ramp up is repeated in the last minute of the protocol.
The present disclosure relates to medical devices such as syringes, auto-injectors, and pens that inhibit oxygen permeation into the fluid chamber. The medical device includes a lubricant-free (e.g., silicone) or a siliconized barrel having an interior surface defining a fluid chamber, an elastomeric stopper, and a plunger rod. In one embodiment, at least a portion of the interior surface of the barrel is reduced to increase the interference fit between the stopper and the barrel. In another embodiment, the stopper may include a plurality of ribs and a valley between each pair of ribs may include a ring member provided in each of the valleys. The ring member includes an oxygen-absorbing, an oxygen-adsorbing material, or both, to bind any oxygen that permeates into the syringe, auto-injector, or pen. In yet another embodiment, the stopper may include a barrier coating including an oxygen barrier material to inhibit or prevent oxygen permeation.
OBJECTIVE: This study investigated morphological changes in the composition of the pelvic floor muscles, degree of atrophy, and urethral function in a rat of simulated birth trauma induced by vaginal distension (VD) model.
METHODS: Female Sprague-Dawley rats were classified into four groups: a sham group, and 1, 2, and 4 weeks post-VD (1 W, 2 W, and 4 W, respectively) groups. We measured the amplitude of urethral response to electrical stimulation (A-URE) to evaluate urethral function. After measuring the muscle wet weight of the pubococcygeus (Pcm) and iliococcygeus (Icm) muscles, histochemical staining was used to classify muscle fibers into Types I, IIa, and IIb, and the occupancy and cross-sectional area of each muscle fiber were determined.
RESULTS: There were 24 Sprague-Dawley rats used. A-URE was significantly lower in the 1 W group versus the other groups. Muscle wet weight was significantly lower in the VD groups versus the sham group for Pcm. The cross-sectional area of Type I Pcm and Icm was significantly lower in the VD groups versus the sham group. Type I muscle fiber composition in Pcm was significantly lower in the VD groups versus the sham groupand lowest in the 2 W group. Type I muscle fiber composition in Icm was significantly lower in the 2 and 4 W groups versus the sham group.
CONCLUSION: Muscle atrophy and changes in muscle composition in the pelvic floor muscles were observed even after improvements in urethral function. These results may provide insight into the pathogenesis of stress urinary incontinence after VD.
Protease inhibitors together with protease sensitive therapeutics or diagnostics are provided, which may be ionically or covalently bound, or unbound. The protease inhibitors and/or protease sensitive moiety may be provided in monomeric, homopolymeric, heteropolymeric (for each of the protease and agent) and/or block copolymeric (combining polymers of agent and inhibitor) form. The inhibitors may be native active or e.g., protease activated. Multiple protease inhibitor peptides may be used in-frame with multiple protease cleavage signals (polymeric protease activated protease inhibitors). Combination with the protease inhibitors with the protease sensitive therapeutic enhances the intact, active molecule local-regional or targeted cell or tissue concentration, peak concentration and/or duration of the therapeutic exposure, thereby increasing its therapeutic efficacy. The protease inhibitors are particularly useful for tumor-targeted therapies and for vaccines.
FIELD: medicine. ^ SUBSTANCE: invention is related to compound of formula (I), (values of radicals are described in formula of invention) or its pharmaceutically acceptable salts, to methods of its production, pharmaceutical composition, which contains it. Application of invention is described for manufacturing of medicinal agent intended for provision of inhibiting action in respect to HDAC in warm-blooded animal, in production of agent used for treatment of malignant tumor. Method is also described for provision of inhibiting action in warm-blooded animal. ^ EFFECT: compounds have inhibiting activity in respect to HDAC. ^ 15 cl, 17 tbl, 24 ex
FIELD: chemistry.SUBSTANCE: present invention relates to the pharmaceutical industry, specifically to heat-inactivated Lactobacillus rhamnosus conjugated with a polysaccharide polymer binder. Method for producing heat-inactivated Lactobacillus rhamnosus RHT-3201 (Lactobacillus rhamnosus KCTC 10833BP), conjugated with polysaccharide polymer binder. Heat-inactivated Lactobacillus rhamnosus RHT-3201 (Lactobacillus rhamnosus KCTC 10833BP), conjugated with a polysaccharide polymer binder. Pharmaceutical composition for the treatment of atopic diseases, wherein the composition contains, as an active ingredient, heat-inactivated Lactobacillus rhamnosus RHT-3201 (Lactobacillus rhamnosus KCTC 10833BP), conjugated with a polysaccharide polymer binder. Use of heat-inactivated Lactobacillus rhamnosus RHT-3201 (Lactobacillus rhamnosus KCTC 10833BP), conjugated with a polysaccharide polymer binder to prepare an agent for treating atopic dermatitis. Method of treating atopy. Composition of the product to reduce the severity of atopic dermatitis. Use of heat-inactivated Lactobacillus rhamnosus RHT-3201 (Lactobacillus rhamnosus KCTC 10833BP), conjugated with a polysaccharide polymer binder to produce a product to reduce the severity of atopic dermatitis. Method for treating or reducing the severity of atopic disease.EFFECT: above-described agents have a higher therapeutic effect in atopic diseases.15 cl, 26 dwg, 13 tbl
EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
The burden of late onset Alzheimer's dementia (LOAD) and its antecedents is increasing without known prevention or cure, and diabetes seems to be one of the strongest risk factors. The predominating causal model in Alzheimer's disease (AD) research is based on the amyloid hypothesis, which posits that amyloid (A) deposition in the brain causes synaptic dysfunction resulting in early memory deficits and progression to mild cognitive impairment (MCI) and dementia. Tau has also gained increasing interest as an AD pathology feature, biomarker, and treatment target.

There are no known curative or preventive measures for LOAD. One of the strongest potential LOAD risk factors is type 2 diabetes, an abnormal elevation of blood glucose associated with microvascular and macrovascular complications including cerebrovascular disease. Many studies have reported an association of diabetes with dementia, including LOAD and vascular dementia (VD). Most studies have found that diabetes is associated with an increased risk of both LOAD and VD, with a stronger association for VD compared with LOAD. Thus, this study focuses on the relation of diabetes, pre-diabetes, and elevated glucose, with AD.
The invention relates to medicine and veterinary medicine, and more specifically to pharmacology, and can be used to prevent viral infections caused by RNA viruses that have a lipid envelope, in particular influenza, transmissible gastroenteritis of swine and other viral infections. The invention expands the range of agents for the claimed purpose. The technical problem of the claimed invention is the expansion of the range of antiviral prophylactic preparations and the formation of new approaches to the problem of preventing human viral diseases, particularly influenza, by intracellular suppression of the virus. A means for preventing viral infections comprises viral material from RNA viruses that have a lipid envelope, and stabilized colloidal selenium at a 1:1 ratio of viral material to stabilized colloidal selenium. The viral material from RNA viruses has titers of 6.0-8.0 Ig TCD 50/ml . To obtain colloidal selenium having particle sizes from 10 to 15 nm, the colloidal selenium is stabilized with polyethylene glycol, and for colloidal selenium having particle sizes from 20 to 40 nm, the colloidal selenium is stabilized with cysteine. The stabilized colloidal selenium has a concentration of 6.0-6.2%.